To rule out the effect of other components in plasma on cancer cells, both anti-HER2 IgG-abundant and -deficient plasma were used to prepare for anti-HER2 IVIg and regular IVIg, respectively, and to conduct the following experiments with CAL27 and SCC25 cell lines (Supplementary Figure S2). This evidence concerns the gene ERBB2 and cancer.